Clinical trial · Interventional
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Randomized Fase II Trial: Comparing Cisplatin, Paclitaxel and Gemcitabine Versus Cisplatin, Paclitaxel, Gemcitabine and Avastin in Patients With Unknown Primary Tumors
NCT00458315CI-TRIAL-00017858withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): never been started
Summary
Brief summary (as posted)
The purpose of this study is to investigate the efficacy of Cisplatin, Paclitaxel, Gemcitabine +/- Avastin (Bevacizumab) in patients with unknown primary tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unknown Primary Tumors | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Avastin (Bevacizumab) | Drug | Bevacizumab | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression Free Survival
- measure
- Response
Secondary outcomes (2)
- measure
- Toxicity
- measure
- Response Duration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Unknown primary tumors 2. ECOG performance status 0-1 3. Adequate kidney, liver and bone marrow function 4. No prior chemotherapy 5. Life expectancy \> 3 months Exclusion Criteria: 1. The following specific syndromes: * Squamous carcinoma limited to cervical glands * Women with adenocarcinoma isolated to axillary nodes * Women with adenocarcinoma isolated to peritoneal involvements * Young men (\<55 years) with growing mid-line tumors where a germ cell tumor could be expected * Neuroendocrine carcinomas 2. Tumor located close to major blood vessels and judged to possess a high risk of serious bleeding 3. Any significant cardiac disease 4. Clinically significant peripheral vascular disease 5. History of myocardial infarction or stroke within 6 months 6. Evidence of coagulopathy 7. Use of ASA, NSAIDs or clopidogrel 8. Pregnancy or breast feeding 9. Ongoing therapeutic anti-coagulation 10. Hypertension with blood pressure \> 150/100 mmHg 11. Brain metastases
References
Publications (0)
Data not yet available
No reference posted for this study.